Market research
SLGL Sol Gel Technologies Ltd
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 253M
- P/E ratio
- Not available
- Analyst target
- 196.6667
- Dividend yield
- Not available
- Beta
- 1.16
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- IL0011417206
- Market cap
- 253M
- P/E ratio
- Not available
- Analyst target
- 196.6667
- Dividend yield
- Not available
- Beta
- 1.16
About
About Sol Gel Technologies Ltd
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SLGL discussion.
5 years, 4 months ago
Sol-Gel Technologies Ltd is currently in a long term uptrend where the price is trading 15.5% above its 200 day moving average.
From a valuation standpoint, the stock is 97.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 31.7.
Sol-Gel Technologies Ltd's total revenue sank by 48.8% to $2M since the same quarter in the previous year.
Its net income has increased by 1.7% to $-6M since the same quarter in the previous year.
Finally, its free cash flow grew by 4.1% to $-10M since the same quarter in the previous year.
Based on the above factors, Sol-Gel Technologies Ltd gets an overall score of 4/5.